PRA Health Sciences Inc (NASDAQ:PRAH) Expected to Announce Earnings of $1.48 Per Share

Analysts expect PRA Health Sciences Inc (NASDAQ:PRAH) to report $1.48 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for PRA Health Sciences’ earnings, with estimates ranging from $1.46 to $1.50. PRA Health Sciences posted earnings per share of $1.31 in the same quarter last year, which indicates a positive year-over-year growth rate of 13%. The company is scheduled to report its next quarterly earnings report on Wednesday, February 26th.

According to Zacks, analysts expect that PRA Health Sciences will report full year earnings of $5.11 per share for the current financial year, with EPS estimates ranging from $5.09 to $5.14. For the next fiscal year, analysts forecast that the business will post earnings of $5.82 per share, with EPS estimates ranging from $5.75 to $5.92. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, October 30th. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.29 by $0.03. PRA Health Sciences had a return on equity of 27.73% and a net margin of 8.00%. The business had revenue of $780.70 million during the quarter, compared to the consensus estimate of $771.64 million. During the same period last year, the business posted $1.13 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis.

A number of brokerages recently issued reports on PRAH. BidaskClub upgraded PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 21st. Wolfe Research upgraded shares of PRA Health Sciences from a “peer perform” rating to an “outperform” rating and set a $123.00 target price for the company in a research note on Thursday, November 14th. Barclays boosted their price target on shares of PRA Health Sciences from $115.00 to $118.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Goldman Sachs Group initiated coverage on shares of PRA Health Sciences in a research report on Thursday, September 19th. They issued a “buy” rating and a $126.00 price target on the stock. Finally, Jefferies Financial Group raised their price objective on shares of PRA Health Sciences from $115.00 to $120.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. PRA Health Sciences currently has an average rating of “Buy” and a consensus price target of $115.78.

Shares of PRAH stock traded up $0.85 on Friday, hitting $108.86. 558,754 shares of the stock were exchanged, compared to its average volume of 525,775. The firm’s 50 day moving average is $103.00 and its two-hundred day moving average is $98.72. PRA Health Sciences has a one year low of $82.12 and a one year high of $115.50. The firm has a market capitalization of $6.89 billion, a PE ratio of 27.70, a P/E/G ratio of 1.48 and a beta of 1.13. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 1.65.

Hedge funds have recently bought and sold shares of the business. Quadrant Capital Group LLC bought a new position in shares of PRA Health Sciences in the third quarter valued at approximately $38,000. Pearl River Capital LLC purchased a new stake in PRA Health Sciences in the 2nd quarter worth approximately $40,000. Cullen Frost Bankers Inc. lifted its stake in PRA Health Sciences by 232.5% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 409 shares of the medical research company’s stock worth $40,000 after purchasing an additional 286 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new position in PRA Health Sciences in the 2nd quarter valued at $49,000. Finally, CENTRAL TRUST Co boosted its holdings in PRA Health Sciences by 20.5% in the 3rd quarter. CENTRAL TRUST Co now owns 792 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 135 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Margin

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.